via University at Buffalo
Model could support the assessment of long-term chronic drug therapies and help clinicians develop more effective treatments for complex diseases
Using artificial intelligence, a team of University at Buffalo researchers has developed a novel system that models the progression of chronic diseases as patients age.
Published in Oct. in the Journal of Pharmacokinetics and Pharmacodynamics, the model assesses metabolic and cardiovascular biomarkers – measurable biological processes such as cholesterol levels, body mass index, glucose and blood pressure – to calculate health status and disease risks across a patient’s lifespan.
The findings are critical due to the increased risk of developing metabolic and cardiovascular diseases with aging, a process that has adverse effects on cellular, psychological and behavioral processes.
“There is an unmet need for scalable approaches that can provide guidance for pharmaceutical care across the lifespan in the presence of aging and chronic co-morbidities,” says lead author Murali Ramanathan, PhD, professor of pharmaceutical sciences in the UB School of Pharmacy and Pharmaceutical Sciences. “This knowledge gap may be potentially bridged by innovative disease progression modeling.”
The model could facilitate the assessment of long-term chronic drug therapies, and help clinicians monitor treatment responses for conditions such as diabetes, high cholesterol and high blood pressure, which become more frequent with age, says Ramanathan.
Additional investigators include first author and UB School of Pharmacy and Pharmaceutical Sciences alumnus Mason McComb, PhD; Rachael Hageman Blair, PhD, associate professor of biostatistics in the UB School of Public Health and Health Professions; and Martin Lysy, PhD, associate professor of statistics and actuarial science at the University of Waterloo.
The research examined data from three case studies within the third National Health and Nutrition Examination Survey (NHANES) that assessed the metabolic and cardiovascular biomarkers of nearly 40,000 people in the United States.
Biomarkers, which also include measurements such as temperature, body weight and height, are used to diagnose, treat and monitor overall health and numerous diseases.
The researchers examined seven metabolic biomarkers: body mass index, waist-to-hip ratio, total cholesterol, high-density lipoprotein cholesterol, triglycerides, glucose and glycohemoglobin. The cardiovascular biomarkers examined include systolic and diastolic blood pressure, pulse rate and homocysteine.
By analyzing changes in metabolic and cardiovascular biomarkers, the model “learns” how aging affects these measurements. With machine learning, the system uses a memory of previous biomarker levels to predict future measurements, which ultimately reveal how metabolic and cardiovascular diseases progress over time.
Original Article: AI-powered computer model predicts disease progression during aging
More from: University at Buffalo | University of Waterloo
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Long-term chronic drug therapies
- Why do people get long COVID? A virus that may cause MS could reveal clues
Scientists are looking at reactivation of latent viruses, and other existing post-infection syndromes, for answers about long-haul COVID-19.
- Anti-inflammatory Drugs May Lead to Chronic Pain
A study found that while anti-inflammatory medications such as Ibuprofen may relieve short-term pain, they can potentially lead to chronic pain.
- Long COVID May Be Chronic, Require Anti-Inflammatory Meds: Study
However, Mainous said it's too early to say whether recovered COVID patients should be put on anti-inflammatory drugs ... a potential treatment." Long COVID should be considered a chronic ...
- How People With Long COVID Can Benefit from Occupational Therapy Programs
FG Trade/Getty Images It’s estimated that up to 50 percent of people who have had COVID-19 will experience long-term health ... of an occupational therapy program for chronic fatigue, she ...
- Hydrea side effects: What you should know
It’s approved by the Food and Drug Administration ... but not the lips chronic myeloid leukemia Hydrea is a type of chemotherapy that’s typically used as a long-term treatment.
Go deeper with Google Headlines on:
Long-term chronic drug therapies
Go deeper with Bing News on:
Progression of chronic diseases
- RPT-FOCUS-U.S. Task Force to consider routine kidney disease screening
(Repeats to wider audience with changes to headline or text) By Deena Beasley May 23 (Reuters) - An influential U.S. panel has added screening for chronic ... slow progression of a disease with ...
- U.S. Task Force to consider routine kidney disease screening
An influential U.S. panel has added screening for chronic kidney disease (CKD) to its list of preventive services under active consideration, the group's chair told Reuters, a move that could help ...
- Chronic wasting disease doesn't affect humans. Experts say tracking, containment key to keeping it that way
A white-tailed buck in the final stages of the always-fatal chronic wasting disease. A CWD-positive deer was confirmed among deer shot by hunters this fall in the Brainerd, Minnesota, area. ST. PAUL — ...
- How to protect yourself against chronic kidney disease
There are often little to no symptoms in chronic cases, which is why screening is so important for catching it in its earliest stages.
- Chronic Obstructive Pulmonary Disease Drugs Market To Rising in the 7MM By 2030, Analysis by DelveInsight
DelveInsight’s Chronic Obstructive Pulmonary Disease (COPD) Market report” puts forward a detailed perspective on epidemiology, current treatment practices, emerging drugs, COPD market share of the ...
